Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis
Primary Purpose
Acute Gastroenteritis
Status
Completed
Phase
Phase 4
Locations
Botswana
Study Type
Interventional
Intervention
Rapid diagnostic
Probiotic
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Acute Gastroenteritis focused on measuring diarrhoea, gastroenteritis, rapid diagnostics, probiotics, sub-Saharan Africa
Eligibility Criteria
Inclusion Criteria:
- acute non-bloody gastroenteritis
Exclusion Criteria:
- diarrhoea > 14 days
- sepsis, pneumonia, UTI, meningitis requiring empiric antibiotic therapy
- malignancy, IBD
- known link to another patient with diarrhoea of defined aetiology
- transferred in already on antimicrobials
- live outside study area
- children with severe acute malnutrition will be eligible for diagnostic arm but not probiotic arm
Sites / Locations
- Princess Marina Hospital
- Scottish Livingstone Hospital
- Bamalete Lutheran Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Placebo Comparator
Experimental
Placebo Comparator
Arm Label
Rapid diagnostics and probiotic
Rapid diagnostics and placebo
Delayed diagnostics and probiotic
Delayed diagnostics and placebo
Arm Description
Outcomes
Primary Outcome Measures
Height z-score (HAZ) adjusted for initial HAZ
Secondary Outcome Measures
mortality
environmental enteropathy score
duration of diarrhoea
Note that presence of diarrhoea will be checked daily during admission. Total duration of diarrhoea will be verified with the caregiver by telephone 7 days after the participant was discharged home.
Weight z-score (WAZ) adjusted for initial WAZ
Full Information
NCT ID
NCT02025452
First Posted
December 28, 2013
Last Updated
March 23, 2017
Sponsor
Jeffrey Pernica
Collaborators
Grand Challenges Canada, BioGaia AB
1. Study Identification
Unique Protocol Identification Number
NCT02025452
Brief Title
Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis
Official Title
Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
March 2014 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jeffrey Pernica
Collaborators
Grand Challenges Canada, BioGaia AB
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have viral gastroenteritis and so not treated with antibiotics - but they may indeed have a treatable cause for their illness. We will conduct a randomized trial to see if rapid testing using novel methods to identify potentially treatable causes of diarrhoea leads to improved outcomes. We will also be randomizing children to probiotic therapy versus placebo (the standard of care) to see if this treatment decreases the duration of diarrhoea. The proposed study is a pilot trial, necessary before embarking on a large multi-centre trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Gastroenteritis
Keywords
diarrhoea, gastroenteritis, rapid diagnostics, probiotics, sub-Saharan Africa
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
76 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Rapid diagnostics and probiotic
Arm Type
Active Comparator
Arm Title
Rapid diagnostics and placebo
Arm Type
Placebo Comparator
Arm Title
Delayed diagnostics and probiotic
Arm Type
Experimental
Arm Title
Delayed diagnostics and placebo
Arm Type
Placebo Comparator
Intervention Type
Other
Intervention Name(s)
Rapid diagnostic
Intervention Description
Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic
Intervention Description
Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
Primary Outcome Measure Information:
Title
Height z-score (HAZ) adjusted for initial HAZ
Time Frame
60 days post-enrollment
Secondary Outcome Measure Information:
Title
mortality
Time Frame
60 days post-enrollment
Title
environmental enteropathy score
Time Frame
60 days post-enrollment
Title
duration of diarrhoea
Description
Note that presence of diarrhoea will be checked daily during admission. Total duration of diarrhoea will be verified with the caregiver by telephone 7 days after the participant was discharged home.
Time Frame
estimated average duration ~ 4 days.
Title
Weight z-score (WAZ) adjusted for initial WAZ
Time Frame
60 days after enrolment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
60 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
acute non-bloody gastroenteritis
Exclusion Criteria:
diarrhoea > 14 days
sepsis, pneumonia, UTI, meningitis requiring empiric antibiotic therapy
malignancy, IBD
known link to another patient with diarrhoea of defined aetiology
transferred in already on antimicrobials
live outside study area
children with severe acute malnutrition will be eligible for diagnostic arm but not probiotic arm
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey Pernica, MD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Princess Marina Hospital
City
Gaborone
Country
Botswana
Facility Name
Scottish Livingstone Hospital
City
Molepolole
Country
Botswana
Facility Name
Bamalete Lutheran Hospital
City
Ramotswa
Country
Botswana
12. IPD Sharing Statement
Learn more about this trial
Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis
We'll reach out to this number within 24 hrs